Showcases Stock ranks Forex

Sarepta Therapeutics (SRPT)
76.05  3.54 (4.88%) 05-14 16:00
Open: 70.28 Pre. Close: 71.02
High: 74.4 Low: 69.8
Volume: 1,070,552 Market Cap: 6,065M
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 76.106 - 76.466 76.466 - 76.805
Low: 68.928 - 69.32 69.32 - 69.688
Close: 75.363 - 76.021 76.021 - 76.638
Stock Technical Analysis
Target: Six months: 91.71
One year: 107.12
Support: Support1: 71.82
Support2: 67.68
Resistance: Resistance1: 78.52
Resistance2: 91.71
Pivot: 72.85
Moving Averages: MA(5): 72.70
MA(20): 72.44
MA(100): 92.71
MA(250): 127.18
MACD: MACD(12,26): -0.44
Signal(12,26,9): -1.02
%K %D: %K(14,3): 59.69
%D(3): 45.36
RSI: RSI(14): 54.64
52-Week: High: 181.83
Low: 69.56
Change(%): -48.2
Average Vol(K): 3-Month: 114427
10-Days: 150125
Price, MAs and Bollinger Bands
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

SRPT has closed below upper band by 12.4%. Bollinger Bands are 71.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to SRPT's normal range. The bands have been in this narrow range for 73 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Fri, 14 May 2021
Sarepta Therapeutics (SRPT) Stock Returns: Average and Excess Return for SRPT after a Fall or Rise - AI Dashboard - Trefis

Wed, 12 May 2021
Where Will Sarepta Therapeutics Inc (SRPT) Stock Go Next After It Is Up 0.66% in a Week? - InvestorsObserver

Thu, 06 May 2021
Sarepta Therapeutics (SRPT) Q1 2021 Earnings Call Transcript - Motley Fool

Wed, 05 May 2021
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq

Wed, 05 May 2021
Sarepta Therapeutics (SRPT) Tops Q1 EPS by 23c, Revenues Beat -

Tue, 04 May 2021
Sarepta Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 79.75
Shares Float (M) 75.62
% Held by Insiders 4.80
% Held by Institutions 89.78
Shares Short (K) 7270
Shares Short Prior Month (K) 6820
Stock Financials
EPS -7.110
Book Value (p.s.) 9.600
Profit Margin -102.60
Operating Margin -104.44
Return on Assets (ttm) -14.7
Return on Equity (ttm) -70.1
Qtrly Rev. Growth 45.0
Gross Profit (p.s.) -3.079
Sales Per Share 6.772
EBITDA (p.s.) -6.735
Qtrly Earnings Growth
Operating Cash Flow (M) 107.47
Levered Free Cash Flow (M) -301.29
Stock Valuation
PE Ratio -10.70
PEG Ratio
Price to Book value 7.92
Price to Sales 11.23
Price to Cash Flow 56.43
Stock Dividends
Dividend Yield
Dividend Growth

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator